Aclaris Therapeutics Inc (ACRS)

Feb 20, 2025

Aclaris Therapeutics (ACRS) Expected to Announce Earnings on Tuesday - MarketBeat

Feb 20, 2025

Feb 20, 2025

Common Warts Market to Expand Significantly by 2034, States - openPR

Feb 20, 2025

Feb 18, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 15.6% in January - MarketBeat

Feb 18, 2025

Feb 18, 2025

Peapod Lane Capital LLC Takes $1 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat

Feb 18, 2025

Feb 17, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World

Feb 17, 2025

Feb 14, 2025

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN

Feb 14, 2025

Feb 12, 2025

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewswire

Feb 12, 2025

Feb 12, 2025

Clinical Data: Revolutionary Dual-Target Drug Shows Promise for Multiple Autoimmune Conditions - StockTitan

Feb 12, 2025

Feb 12, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Feb 12, 2025

Feb 12, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Feb 12, 2025

Feb 11, 2025

Financial Metrics Check: Aclaris Therapeutics Inc (ACRS)’s Ratios for Trailing Twelve Months - The Dwinnex

Feb 11, 2025

Feb 11, 2025

Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule - Seeking Alpha

Feb 11, 2025

Feb 10, 2025

What is Leerink Partnrs' Forecast for ACRS FY2029 Earnings? - MarketBeat

Feb 10, 2025

Feb 10, 2025

H.C. Wainwright gives a Buy recommendation for Aclaris Therapeutics Inc (ACRS) - Knox Daily

Feb 10, 2025

Feb 10, 2025

Leerink Partnrs Has Negative Outlook of ACRS FY2025 Earnings - MarketBeat

Feb 10, 2025

Feb 08, 2025

Research Analysts Issue Forecasts for ACRS FY2029 Earnings - Armenian Reporter

Feb 08, 2025

Feb 08, 2025

StockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Sell - Defense World

Feb 08, 2025

Feb 07, 2025

Aclaris Therapeutics Inc (ACRS) Shares Decline Despite Market Challenges - The News Heater

Feb 07, 2025

Feb 07, 2025

Aclaris Therapeutics Inc (ACRS) Stock: Navigating a Year of Stock Volatility - The InvestChronicle

Feb 07, 2025

Feb 07, 2025

What is Leerink Partnrs’ Forecast for ACRS FY2025 Earnings? - Armenian Reporter

Feb 07, 2025

Feb 07, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Analysts - MarketBeat

Feb 07, 2025

Feb 06, 2025

Aclaris Therapeutics Inc [ACRS] Records 50-Day SMA of $2.98 - Knox Daily

Feb 06, 2025

Feb 05, 2025

Aclaris Therapeutics forms new Scientific Advisory Board - MSN

Feb 05, 2025

Feb 05, 2025

The Aclaris Therapeutics Inc (ACRS) had a good session last reading, didn’t it? - US Post News

Feb 05, 2025

Feb 04, 2025

Aclaris Therapeutics Inc (ACRS)’s Market Momentum: Closing Strong at 2.40, Down -3.23 - The Dwinnex

Feb 04, 2025

Feb 04, 2025

Healthy Upside Potential: Aclaris Therapeutics Inc (ACRS) - SETE News

Feb 04, 2025

Feb 04, 2025

Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex

Feb 04, 2025

Feb 04, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat

Feb 04, 2025

Feb 03, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Cut to Sell at StockNews.com - MarketBeat

Feb 03, 2025

Feb 02, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Cantor Fitzgerald - Defense World

Feb 02, 2025

Feb 01, 2025

Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts - MSN

Feb 01, 2025

Feb 01, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in January - Defense World

Feb 01, 2025

Jan 31, 2025

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewswire

Jan 31, 2025

Jan 30, 2025

Aclaris Therapeutics forms new Scientific Advisory Board By Investing.com - Investing.com Canada

Jan 30, 2025

Jan 30, 2025

Aclaris Therapeutics Appoints Marianne Mann and Zuzana Diamant to Scientific Advisory Board - citybiz

Jan 30, 2025

Jan 25, 2025

Assenagon Asset Management S.A. Acquires 211,585 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Jan 25, 2025

Jan 25, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Assenagon Asset Management S.A. - MarketBeat

Jan 25, 2025

Jan 23, 2025

Cantor Fitzgerald Comments on ACRS FY2025 Earnings - Defense World

Jan 23, 2025